212 related articles for article (PubMed ID: 12644961)
1. Thalidomide: from tragedy to promise.
von Moos R; Stolz R; Cerny T; Gillessen S
Swiss Med Wkly; 2003 Feb; 133(5-6):77-87. PubMed ID: 12644961
[TBL] [Abstract][Full Text] [Related]
2. Current status of thalidomide in the treatment of cancer.
Rajkumar SV
Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
Breitkreutz I; Anderson KC
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide: mechanisms of action.
Paravar T; Lee DJ
Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
[TBL] [Abstract][Full Text] [Related]
5. [Thalidomide--failure or success? A controversial drug during the last fifty years--the pendulum swings--a renaissance for thalidomide?].
Dalhoff KP; Poulsen HE
Ugeskr Laeger; 2000 Jan; 162(1):52-3. PubMed ID: 10658498
[No Abstract] [Full Text] [Related]
6. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug].
Borges Lde G; Frõehlich PE
Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.
Ribatti D; Vacca A
Leukemia; 2005 Sep; 19(9):1525-31. PubMed ID: 15973447
[TBL] [Abstract][Full Text] [Related]
8. Recent advances of IMiDs in cancer therapy.
Li S; Gill N; Lentzsch S
Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide: dual benefits in palliative medicine and oncology.
Davis MP; Dickerson ED
Am J Hosp Palliat Care; 2001; 18(5):347-51. PubMed ID: 11565189
[TBL] [Abstract][Full Text] [Related]
10. [Thalidomide in treatment of connective diseases and vasculities].
Maruotti N; Cantatore FP; Ribatti D
Reumatismo; 2006; 58(3):187-90. PubMed ID: 17013434
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in cancer medicine.
Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA
Ann Oncol; 2004 Aug; 15(8):1151-60. PubMed ID: 15277253
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide. A new beginning.
Valorie AM
Cancer Pract; 2000; 8(2):101-3. PubMed ID: 11898173
[No Abstract] [Full Text] [Related]
13. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of lenalidomide in hematological malignancies.
Kotla V; Goel S; Nischal S; Heuck C; Vivek K; Das B; Verma A
J Hematol Oncol; 2009 Aug; 2():36. PubMed ID: 19674465
[TBL] [Abstract][Full Text] [Related]
15. [Thalidomide: the revival].
Grosbois B; Duguet C
Rev Med Interne; 2001 Jan; 22(1):5-7. PubMed ID: 11218298
[No Abstract] [Full Text] [Related]
16. [New indications for thalidomide?].
Tuinmann G; Hegewisch-Becker S; Hossfeld DK
Dtsch Med Wochenschr; 2001 Oct; 126(42):1178-82. PubMed ID: 11607859
[No Abstract] [Full Text] [Related]
17. Thalidomid: current role in the treatment of non-plasma cell malignancies.
Kumar S; Witzig TE; Rajkumar SV
J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide: current and potential clinical applications.
Calabrese L; Fleischer AB
Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic drugs: insights into drug development from endostatin, avastin and thalidomide.
Holaday JW; Berkowitz BA
Mol Interv; 2009 Aug; 9(4):157-66. PubMed ID: 19720747
[No Abstract] [Full Text] [Related]
20. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
